Daily OCS doses of 1.0 mg/kg or less (maximum daily dose 80 mg) were allowed at the start of DSG therapy.
Usually for acute pain, NSAIDs are taken 200-400 mg every 6-8 hours, as needed, not to exceed total daily doses of 1200 mg; for patients weighing 60 kg or less, total daily dose should not exceed 20/mg/day.
A recent study showed that an enteric-release cysteamine required less frequent daily dosing.
At least one study has demonstrated that patients are willing to forego treatment benefits to reduce the number of daily insulin injections, 46 and multiple other studies have demonstrated that less frequent daily dosing is preferred and may improve likely adherence to treatment with oral antihyperglycemic agents in patients with T2D 47 or with other chronic conditions.
The only consistent advantage of such combined therapy is reduced insulin dose requirements, which may result in less daily injections, easier dose titration, and improved compliance (46).
We classified drug intake according to the following principles: within each six-month period of follow-up, we added up the total number of dispensed ASA and categorized drug intake into three different groups; unexposed individuals (0 daily doses), partially exposed individuals (less than 1 daily dose) and fully exposed individuals (1 or more daily doses of either 75 or 160 mg).
The mean (SD) intake of vitamin D from food was 167 (±87) IU/day (Table 1), which is notably less than the recommended daily dose of 400 IU/day.
Treatment options include oral anti-fungal medications and physical methods, the former often requiring lengthy courses, and responses vary. 1, 2 Here, we speculate that terbinafine dosed at 500 mg daily for the first 2 weeks, a less commonly prescribed higher daily dose, may have been beneficial.
Two patients (7%) are continuing to receive erlotinib without evidence of progression, both at a daily dose of less than 150 mg (due to skin toxicity).
